RxDoctor Payments Data

Monica Recine, MD

Clinical Pathology/Laboratory Medicine · Miami Beach, FLNPI 1407886757

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Genentech USA, Inc. at 24.3% of the total. Reporting peaked in 2019 at $411 and has fallen 60.0% since, to $164 in 2023.

$1,074in general payments, 2019–2025

Across 22 payments — averaging $48.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$261
  • AstraZeneca$221
  • Merck$141
  • Myriad Genetic Laboratories, Inc.$125
  • Roche Diagnostics Corporation$108
  • Novartis$85
  • plus $133 from 6 others

What the payments were for

  • Food & beverage$1,074100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,074 in reported general payments places this provider in the 75th percentile of 43 clinical pathology/laboratory medicine providers in Florida.

See all clinical pathology/laboratory medicine providers in Florida

Medicare billing

Part B allowed, 2024
$44,446
Medicare patients
473
Services billed
1,194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other clinical pathology/laboratory medicine in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →